This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2,
double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with
placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus
Erythematosus (SLE). Study details include:
Study duration: 36 weeks
Treatment duration: 24 weeks
Visit frequency: every 2 weeks
Systemic Lupus Erythematosus
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.